Sanofi-Aventis SA (Sanofi-Aventis) has appointed Jean-Pierre Lehner as its senior vice-president (SVP), chief medical officer (CMO). He was previously SVP, medical & regulatory affairs. Jean-Pierre Lehner reports to Marc Cluzel, SVP, research & development. The CMO will also chair the internal benefit/risk assessment committee created in 2008 and which has direct accountability for its conclusions to the chief executive officer.
Marc Cluzel said: “The newly created role of Chief Medical Officer is a further demonstration internally and externally of the company’s commitment to patient well being”.
SVP, CMO, position combines all of the functions related to patient safety to enhance the clarity of purpose and accountability within the company. Pharmacovigilance and regulatory affairs will report to the CMO.
Jean-Pierre Lehner holds a Medical degree from the School of Medicine University of Paris, France. After spending four years as Chef de Clinique, assistant of Paris Hospitals, Department of Cardiology (Pr Tricot), Hôpital Bichat, Paris, France, Jean-Pierre Lehner joins Roussel Laboratories in 1981 as medical director (1981-1986), then he is named medical director of Roussel-Uclaf (1986-1992). He is successively senior director of clinical investigations of Sanofi Recherche (1992-1996), scientific senior director of Sanofi Winthrop (1996-2002), vice president medical affairs Europe of sanofiaventis (2003-2005). As from 2005, Jean-Pierre Lehner was senior vice-president, medical & regulatory affairs sanofi-aventis.